SCHEMBL14018083

SCHEMBL14018083

CCOC(=O)[C@H]1[C@@H]2Oc3cc(Oc4ccc(C(F)(F)F)cc4OC(F)F)ccc3[C@@H]21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 5/20 0.57
▸ CYP2C9 P11712 3/20 0.44
▸ KCNH2 Q12809 1/20 0.44
▸ CACNA1C Q13936 1/20 0.44
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ NPSR1 Q6W5P4 3/20 0.36
▸ CYP1A2 P05177 2/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ MAPT P10636 4/20 0.36
▸ ATM Q13315 3/20 0.36
▸ LMNA P02545 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ HTT P42858 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ SCN8A Q9UQD0 2/20 0.33
▸ SCN10A Q9Y5Y9 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14018206 1.00 FFAR1 (0.57) FFAR1CYP2C9KCNH2CACNA1CMEN1
SCHEMBL4819528 1.00 FFAR1 (0.57) FFAR1CYP2C9KCNH2CACNA1CMEN1
SCHEMBL4864532 0.87 FFAR1 (0.74) FFAR1CYP2C9KCNH2CACNA1CMEN1
SCHEMBL4820432 0.87 FFAR1 (0.74) FFAR1CYP2C9KCNH2CACNA1CMEN1
SCHEMBL4864522 0.87 FFAR1 (0.74) FFAR1CYP2C9KCNH2CACNA1CMEN1
SCHEMBL4827147 0.86 FFAR1 (0.76) FFAR1CYP2C9KCNH2MEN1KMT2A
SCHEMBL4827290 0.86 FFAR1 (0.61) FFAR1CYP2C9KCNH2CACNA1CMEN1
SCHEMBL4820414 0.83 FFAR1 (0.55) FFAR1CYP2C9KCNH2CACNA1CMEN1
SCHEMBL4823976 0.81 FFAR1 (0.45) FFAR1CYP2C9KCNH2CACNA1CMEN1
SCHEMBL14018258 0.81 FFAR1 (0.45) FFAR1CYP2C9KCNH2CACNA1CMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442808-B2 e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia MERCK & CO., INC. (US) 2008-10-28 — — US disclosed
US-7442808-B2 e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia MERCK & CO., INC. (US) 2008-10-28 — — US disclosed
WO-2007136572-A2 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK & CO., INC. (US) 2007-11-29 — — WO disclosed
WO-2007136573-A2 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK & CO., INC. (US) 2007-11-29 — — WO disclosed
US-20070265332-A1 Antidiabetic bicyclic compounds MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
US-20070265332-A1 Antidiabetic bicyclic compounds MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265332-A1 Antidiabetic bicyclic compounds GPR119, GPR65, FFAR4 FFAR1 9/4885CYP2C9 573/4885KCNH2 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback